Promising Results from Breast Cancer Study Using Sanarus Technologies Visica 2™ Cryoablation Treatment System

Minimally Invasive Procedure Showcases Future Treatment Options

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
I am excited for the future as this study and our FROST clinical trial create a path forward in the adoption of cryotherapy for malignant tumors, and an evolution in the standard of care.

Pleasanton, CA (PRWEB) May 02, 2014

Sanarus Technologies welcomes the release of an abstract for the recently completed ACOSOG (Alliance) Z1072 Clinical Trial. The company’s proprietary Visica 2 Cryoablation Treatment System was used exclusively in the study, titled “A Phase II Trial Exploring the Success of Cryoablation in the Treatment of Invasive Breast Carcinoma”.

The abstract states that “Cryoablation Shows Promise as a Non-Surgical Treatment for Early Stage Breast Cancer”. Cryoablation is an existing alternative to a lumpectomy and has been available for the treatment of benign breast lesions for over 10 years. Past studies using the Visica® and Visica 2 have pointed to cryoablation as a potential treatment for early stage breast cancer. This 5-year study provided compelling evidence of what the future of breast cancer treatment could look like for patients faced with the disease. Sanarus CEO, BJ Hardman stated, “Women deserve a minimally invasive option and we are thrilled about the potential of advancing the treatment of breast cancer by providing patients with an alternative.”

After examination of pathology, the study found that in tumor sizes of less than 1 cm, cryoablation resulted in 100% eradication of the tumor with no evidence of IDC (Invasive Ductal Cancer) or DCIS (Ductal Carcinoma in situ). The study investigated cryoablation of early stage breast cancer followed by surgical excision and evaluation of pathology for evidence of remaining cancerous tissue. "Sanarus has been the leader in the cryoablation of non-cancerous breast lesions for over a decade. I am excited for the future as this study and our FROST clinical trial create a path forward in the adoption of cryotherapy for malignant tumors, and an evolution in the standard of care,” stated Lee Story, President

This week Sanarus will be participating as an exhibitor at the American Society of Breast Surgeons (ASBrS) annual conference in Las Vegas. The company will be conducting hands-on demonstrations of the cryotherapy process using the Visica 2 in Booth 511. The company is highly encouraged with the results as outlined in the abstract and envisions the day when cryotherapy is the standard of care for early stage breast tumors.        

Sanarus Technologies is a privately held medical device company pioneering minimally invasive breast cryotherapy solutions. Headquartered in Pleasanton, California, Sanarus is a woman-owned business with all products manufactured in the USA.


Contact